Bayer plans to open new cell therapy manufacturing facility with an investment of US$250 million. The facility will be loacted in California, USA.
The cell therapy facility is designed to deliver advanced cell therapies to patients worldwide.
The facility introduces a cutting-edge setup with adaptable, modular areas specifically designed for cell culture, viral transduction, and automated filling of cell therapies.
This facility harnesses the vast expertise of Biotech@Bayer in iPSC and CAR-T characterisation, process development, analytics, and the seamless transition from clinical testing to large-scale commercial production.
The investment made will significantly bolster the production of materials necessary for both the clinical trials and the potential commercial release of bemdaneprocel (BRT-DA01), an investigational cell therapy developed by BlueRock Therapeutics.
The newly established facility will not only aid in the current production of cell therapies but is strategically positioned to accommodate the future advancements and expansion of the cell therapy portfolio.
The support provided by this investment will play a crucial role in advancing the development, testing, and, hopefully, the eventual availability of this innovative cell therapy for patients suffering from Parkinson's Disease.
This manufacturing facility plays a pivotal role in bridging the gap between the developmental stages and the delivery of impactful cell therapies to patients who are in need of effective treatments.
Type New Construction
Budget US$250 million